Drug regimen for treatment of cerebral ischemia
AssigneeShimojani, LLC
InventorsLawrence M. Kauvar, Damir Janigro
Life of this patent
Estimating the term…
Abstract
Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
Claims11
A method of treatment to reduce neuronal damage caused by a cerebral ischemic event in a human patient, said method comprising administering to said patient an effective amount of a thrombolytic agent and an effective amount of an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction (VEGF-RST), wherein
- (i) the inhibitor is selected from the group consisting of ranibizumab and bevacizumab, and wherein the effective amount of the inhibitor is 0.1-2.5 mg in a 70 kg patient with adjustments for patients of different weights;
- (ii) the effective amount of said inhibitor provides inhibition of >50% of said VEGF-RST activity over 24 hours;
- and
- (iii) the serum concentration level of said inhibitor is reduced below this pharmacologically active level at least by 48 hours after administration.
A method of treatment to reduce neuronal damage caused by a cerebral ischemic event in a human patient, said method comprising mechanically removing a blood clot associated with said ischemia event and administering in association with said removing a measured dose of an inhibitor of VEGF-RST, wherein:
- the inhibitor is selected from the group consisting of ranibizumab and bevacizumab, and wherein the effective amount of the inhibitor is 0.1-2.5 mg in a 70 kg patient with adjustments for patients of different weights;
- and
- the inhibitor is effective to inhibit >50% of signal transduction over 24 hours and wherein the serum concentration level of said inhibitor is reduced below this pharmacologically active level at least by 48 hours after administration.
Dependencies are inferred from the claim text.